GEN - Genetic Engineering and Biotechnology News2h
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Stocktwits on MSN2d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
Clinical Trials Arena on MSN3d
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...
The American Journal of Managed Care1d
Delandistrogene Moxeparvovec Shows Long-Term Impacts at 3 and 5 Years in DMD
Study results support the role of functional dystrophin and suggest that delandistrogene moxeparvovec stabilizes or slows ...
MPR2d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
Northern Minnesota boy is first American to receive groundbreaking treatment for muscular dystrophy
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
GEN - Genetic Engineering and Biotechnology News4d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
BioSpace2d
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
Opinion
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
The American Journal of Managed Care4d
EMBARK Data Show Continued Improvements With DMD Gene Therapy
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...